{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:35:05Z","timestamp":1787016905992,"version":"build-2736575974"},"reference-count":50,"publisher":"BMJ","issue":"4","funder":[{"name":"the International S&T Cooperation Program of China"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2018,2,23]]},"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The aim of this study was to explore the prognostic value of ki67 as a marker in patients with non-muscle invasive bladder cancer (NMIBC) treated with BCG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Studies were systematically retrieved from the relevant databases (Web of Science, PubMed, Cochrane Library and Embase), and the expiry date was May 2017. The research steps referred to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 11 studies that complied with the inclusion criteria were included. The expression of ki67 was not statistically significantly associated with recurrence-free survival (RFS) (HR 1.331; 95%\u2009CI 0.980 to 1.809). No significant heterogeneity was found among all included studies (\n                      <jats:italic>\n                        I\n                        <jats:sup>2<\/jats:sup>\n                      <\/jats:italic>\n                      =36.7%, p=0.148). The expression of ki67 was statistically significantly associated with progression-free survival (PFS) (HR 2.567; 95%\u2009CI 1.562 to 4.219), and the overexpression of ki67 was the risk factor for PFS. Significant heterogeneity was noted among all the included studies (\n                      <jats:italic>\n                        I\n                        <jats:sup>2<\/jats:sup>\n                      <\/jats:italic>\n                      =55.6%, p=0.021). The studies that might cause heterogeneity were excluded using the Galbraith plot, and then the meta-analysis was performed again. The results showed that the expression of ki67 was still associated with PFS (HR 2.922; 95%\u2009CI 2.002 to 4.266).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The overexpression of ki67 was the risk factor for PFS, and the relationship between the expression of ki67 and RFS was not statistically significant in patients with NMIBC treated with BCG intravesical immunotherapy. Well-designed, prospective, with a large sample size are still needed to validate the findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2017-019635","type":"journal-article","created":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T11:10:20Z","timestamp":1523963420000},"page":"e019635","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":20,"title":["Prognostic value of ki67 in BCG-treated non-muscle invasive bladder cancer: a meta-analysis and systematic review"],"prefix":"10.1136","volume":"8","author":[{"given":"Yuhui","family":"He","sequence":"first","affiliation":[{"name":"Peking University China-Japan Friendship School of Clinical Medicine, Beijing, China"},{"name":"Department of Urology, China-Japan Friendship Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Wang","sequence":"additional","affiliation":[{"name":"College of Psychology, North China University of Science and Technology, Tangshan, Hebei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Zhou","sequence":"additional","affiliation":[{"name":"Peking University China-Japan Friendship School of Clinical Medicine, Beijing, China"},{"name":"Department of Urology, China-Japan Friendship Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, China-Japan Friendship Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenshan","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Urology, China-Japan Friendship Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology, China-Japan Friendship Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yisen","family":"Deng","sequence":"additional","affiliation":[{"name":"Peking University China-Japan Friendship School of Clinical Medicine, Beijing, China"},{"name":"Department of Urology, China-Japan Friendship Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,4,17]]},"reference":[{"key":"2025121401361641000_8.4.e019635.1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-009-0383-3"},{"key":"2025121401361641000_8.4.e019635.2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21262"},{"key":"2025121401361641000_8.4.e019635.3","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0094-0143(21)00412-2","article-title":"Cytologic and histologic features of superficial bladder cancer","volume":"19","author":"Ro","year":"1992","journal-title":"Urol Clin North Am"},{"key":"2025121401361641000_8.4.e019635.4","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/bju.13760","article-title":"Guideline of guidelines: non-muscle-invasive bladder cancer","volume":"119","author":"Woldu","year":"2017","journal-title":"BJU Int"},{"key":"2025121401361641000_8.4.e019635.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0302-2838(02)00068-4"},{"key":"2025121401361641000_8.4.e019635.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.04.009"},{"key":"2025121401361641000_8.4.e019635.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.12.024"},{"key":"2025121401361641000_8.4.e019635.8","first-page":"423","article-title":"Failure of Bacillus Calmette-Gu\u00e9rin therapy in non-muscle-invasive bladder cancer: definition and treatment options","volume":"69","author":"Gual Frau","year":"2016","journal-title":"Arch Esp Urol"},{"key":"2025121401361641000_8.4.e019635.9","first-page":"189","article-title":"Intravesical Bacillus Calmette-Guerin for treating bladder cancer","volume":"23","author":"Boyd","year":"2003","journal-title":"Urol Nurs"},{"key":"2025121401361641000_8.4.e019635.10","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4103\/0974-7796.84954","article-title":"Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Gu\u00e9rin","volume":"3","author":"Alkhateeb","year":"2011","journal-title":"Urol Ann"},{"key":"2025121401361641000_8.4.e019635.11","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000149163.08521.69"},{"key":"2025121401361641000_8.4.e019635.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.05.033"},{"key":"2025121401361641000_8.4.e019635.13","first-page":"743","article-title":"Histological and immunohistochemical markers for progression prediction in transurethrally resected high-grade non-muscle invasive bladder cancer","volume":"8","author":"Kim","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"2025121401361641000_8.4.e019635.14","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.urolonc.2011.06.004","article-title":"Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?","volume":"31","author":"Park","year":"2013","journal-title":"Urol Oncol"},{"key":"2025121401361641000_8.4.e019635.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0302-2838(02)00580-8"},{"key":"2025121401361641000_8.4.e019635.16","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000343431","article-title":"Prognostic factors including Ki-67 and p53 in Bacillus Calmette-Gu\u00e9rin-treated non-muscle-invasive bladder cancer: a prospective study","volume":"90","author":"Oderda","year":"2013","journal-title":"Urol Int"},{"key":"2025121401361641000_8.4.e019635.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)61770-1"},{"key":"2025121401361641000_8.4.e019635.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0302-2838(03)00048-4"},{"key":"2025121401361641000_8.4.e019635.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.08.065"},{"key":"2025121401361641000_8.4.e019635.20","doi-asserted-by":"publisher","DOI":"10.1038\/nrn3475"},{"key":"2025121401361641000_8.4.e019635.21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"2025121401361641000_8.4.e019635.22","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z"},{"key":"2025121401361641000_8.4.e019635.23","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8"},{"key":"2025121401361641000_8.4.e019635.24","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"2025121401361641000_8.4.e019635.25","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"2025121401361641000_8.4.e019635.26","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwn340"},{"key":"2025121401361641000_8.4.e019635.27","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1007\/s00394-014-0667-2","article-title":"Dietary carrot consumption and the risk of prostate cancer","volume":"53","author":"Xu","year":"2014","journal-title":"Eur J Nutr"},{"key":"2025121401361641000_8.4.e019635.28","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.11049"},{"key":"2025121401361641000_8.4.e019635.29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2012.10996.x"},{"key":"2025121401361641000_8.4.e019635.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.05.041"},{"key":"2025121401361641000_8.4.e019635.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.07.016"},{"key":"2025121401361641000_8.4.e019635.32","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0022-5347(17)35397-1","article-title":"Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer","volume":"150","author":"Kiemeney","year":"1993","journal-title":"J Urol"},{"key":"2025121401361641000_8.4.e019635.33","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.4049\/jimmunol.133.4.1710","article-title":"Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67","volume":"133","author":"Gerdes","year":"1984","journal-title":"J Immunol"},{"key":"2025121401361641000_8.4.e019635.34","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9"},{"key":"2025121401361641000_8.4.e019635.35","first-page":"867","article-title":"Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67","volume":"138","author":"Gerdes","year":"1991","journal-title":"Am J Pathol"},{"key":"2025121401361641000_8.4.e019635.36","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0302-2838(01)00038-0","article-title":"p53 and ki67 expression as prognostic factors for cancer-related survival in stage T1 transitional cell bladder carcinoma","volume":"41","author":"Rodr\u00edguez-Alonso","year":"2002","journal-title":"Eur Urol"},{"key":"2025121401361641000_8.4.e019635.37","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/bjc.2015.179","article-title":"Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma","volume":"113","author":"McCormick Matthews","year":"2015","journal-title":"Br J Cancer"},{"key":"2025121401361641000_8.4.e019635.38","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2217\/bmm-2015-0064","article-title":"A meta-analysis of biomarkers for the prognosis of triple-negative breast cancer patients","volume":"10","author":"Gui","year":"2016","journal-title":"Biomark Med"},{"key":"2025121401361641000_8.4.e019635.39","first-page":"239","article-title":"High expression of KIF14 is associated with poor prognosis in patients with epithelial ovarian cancer","volume":"21","author":"Qiu","year":"2017","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2025121401361641000_8.4.e019635.40","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003337","article-title":"High Ki-67 immunohistochemical reactivity correlates with poor prognosis in bladder carcinoma: a comprehensive meta-analysis with 13,053 patients involved","volume":"95","author":"Luo","year":"2016","journal-title":"Medicine"},{"key":"2025121401361641000_8.4.e019635.41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119476","article-title":"p53 Status correlates with the risk of recurrence in non-muscle invasive bladder cancers treated with Bacillus Calmette-Gu\u00e9rin: a meta-analysis","volume":"10","author":"Zhou","year":"2015","journal-title":"PLoS One"},{"key":"2025121401361641000_8.4.e019635.42","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12957-016-0890-9","article-title":"p53 status correlates with the risk of progression in stage T1 bladder cancer: a meta-analysis","volume":"14","author":"Du","year":"2016","journal-title":"World J Surg Oncol"},{"key":"2025121401361641000_8.4.e019635.43","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207116"},{"key":"2025121401361641000_8.4.e019635.44","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.201009059"},{"key":"2025121401361641000_8.4.e019635.45","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2004.022939"},{"key":"2025121401361641000_8.4.e019635.46","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603784"},{"key":"2025121401361641000_8.4.e019635.47","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/00365590601183055","article-title":"Prognostic value of p53, Ki-67, microstaging and microvessel density in pT1G3 bladder tumors: creation of risk groups for progression","volume":"41","author":"Queipo-Zaragoza","year":"2007","journal-title":"Scand J Urol Nephrol"},{"key":"2025121401361641000_8.4.e019635.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2003.11.011"},{"key":"2025121401361641000_8.4.e019635.49","doi-asserted-by":"publisher","DOI":"10.1159\/000049768"},{"key":"2025121401361641000_8.4.e019635.50","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1442-2042.1997.tb00307.x","article-title":"Prognostic markers of intravesical bacillus Calmette-Gu\u00e9rin therapy for multiple, high-grade, stage T1 bladder cancers","volume":"4","author":"Lee","year":"1997","journal-title":"Int J Urol"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2017-019635","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T09:36:24Z","timestamp":1765704984000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2017-019635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":50,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,4,17]]},"published-print":{"date-parts":[[2018,4]]}},"alternative-id":["10.1136\/bmjopen-2017-019635"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2017-019635","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4]]}}}